Melatonin Supplements May Protect Night Shift Workers From DNA Damage, New Trial Shows

A groundbreaking prospective clinical trial by the BC Cancer Research Institute has revealed that a low dose of melatonin can significantly boost DNA repair in night shift workers, a demographic at elevated risk of cancer. Administering just 3 mg of melatonin before daytime sleep led to an 80% increase in a crucial DNA repair biomarker, offering a tangible, low-cost prophylactic strategy against the cellular damage inherent to chronodisruption. This finding arrives amid increasing global concern over the long-term health ramifications of night shift work, which affects hundreds of millions globally. The World Health Organization's International Agency for Research on Cancer (IARC) has classified shift work involving circadian rhythm disruption as a Group 2A carcinogen due to its link with increased oxidative stress and impaired DNA repair. Prior interventions have largely focused on optimizing schedules or light exposure, making a direct biochemical intervention like melatonin a significant new avenue in occupational health. While preliminary, these results are poised to catalyze larger, multi-center trials to validate efficacy and determine optimal dosage and duration for sustained protection. If confirmed, this simple supplement could become a standard recommendation, transforming occupational health guidelines for industries reliant on 24/7 operations and offering tangible cancer risk mitigation for a vulnerable workforce. Regulators and employers will be watching closely as further research unfolds.